Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design
Archives of Cardiovascular Diseases · 2025-02 · 118 (2) · 106-115
DOI: 10.1016/j.acvd.2024.12.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Cardiovascular Diseases, 2025-02. Verfasst von Joe-Elie Salem und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of pharmacology, Sorbonne Université, Inserm, CIC-1901, AP-HP, Hôpital Pitié-Salpêtrière, 75013 Paris, France. Electronic address: joe-eli…. Hauptthemen laut MEDLINE: Myocarditis, Immune Checkpoint Inhibitors, Abatacept, Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French Federation of Cardiology.
Abstract (Originalsprache)
BACKGROUND: Immune checkpoint inhibitor (ICI)-induced myocarditis is a life-threatening adverse drug reaction. Abatacept (a CTLA-4-immunoglobulin fusion protein) has been proposed as a compassionate-use treatment for ICI myocarditis (in combination with corticosteroids and ruxolitinib) but no clinical trial has yet been performed. The abatacept dose can be adjusted using real-time assessment of its target, the CD86 receptor occupancy on circulating monocytes (CD86RO). METHODS: The ACHLYS trial is an ongoing dose-finding, Phase II, randomized, double-blind trial in which three different abatacept doses are being tested, aiming to reach CD86RO≥80% after the first dose and sustainably during the first 3 weeks of ICI myocarditis treatment (primary outcome). Adult patients with cancer presenting severe or corticosteroid-resistant ICI myocarditis have been included. ICI are withheld after inclusion and for the study duration. Abatacept is administered by intravenous injection on Days 1, 5±2 and 14±2 at 10, 20 or 25mg/kg depending on the randomization arm (n=7 per arm) with concomitant ruxolitinib and corticosteroids. After evaluation of the primary outcome on Day 21, complementary injections of abatacept (for≤3 months) and a ruxolitinib/corticosteroids weaning strategy are standardized depending on criteria evaluating resolution of ICI myocarditis severity (troponin T level and clinical assessment). Secondary objectives compare immunological, myocardial and muscular proxies of treatment response between randomization arms, and cancer progression-free and overall survivals up to 1 year. CONCLUSION: The ACHLYS trial will define the most appropriate starting dose of abatacept to treat life-threatening ICI myocarditis, in combination with ruxolitinib and corticosteroids. CLINICALTRIALS: GOV: NCT05195645.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of pharmacology, Sorbonne Université, Inserm, CIC-1901, AP-HP, Hôpital Pitié-Salpêtrière, 75013 Paris, France. Electronic address: joe-elie.salem@aphp.fr.
- Department of Cardiology, AP-HP, Hôpital Saint-Antoine, 75012 Paris, France.
- Département de santé publique, unité de recherche clinique PSL-CFX, CIC-1901, Sorbonne Université, Inserm, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpêtrière, 75013 Paris, Franc…
- Department of pharmacology, Sorbonne Université, Inserm, CIC-1901, AP-HP, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
- Department of Internal Medicine, Sorbonne Université, Inserm, AP-HP, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Förderung
- French Federation of Cardiology
Zitieren
APA
Salem, J. E., Ederhy, S., Belin, L., Zahr, N., Tubach, F., Procureur, A., Allenbach, Y., Rosenzwjag, M., & Bretagne, M. (2025). Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design. Archives of Cardiovascular Diseases, 118(2), 106-115. https://doi.org/10.1016/j.acvd.2024.12.005
Vancouver
Salem JE, Ederhy S, Belin L, Zahr N, Tubach F, Procureur A, et al. Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design. Archives of Cardiovascular Diseases. 2025;118(2):106-115. doi:10.1016/j.acvd.2024.12.005
BibTeX
@article{Salem2025,
author = {Salem, Joe-Elie and Ederhy, Stephane and Belin, Lisa and Zahr, Noel and Tubach, Florence and Procureur, Adrien and Allenbach, Yves and Rosenzwjag, Michelle and Bretagne, Marie},
title = {Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design},
journal = {Archives of Cardiovascular Diseases},
year = {2025},
volume = {118},
number = {2},
pages = {106--115},
doi = {10.1016/j.acvd.2024.12.005}
}
EUVIMED